$10 Billion Deal, page-13066

I really don't know how they took so long to do the Covid Trial,
And how they are possibly still waiting on preliminary results,
Let alone the finalised Covid results which could well take months,
To write up and interpret the data etc....

If they had of stuck to the SARS treatment and results,
From over 20 Years ago and just completed something for a change,
it would have been right there ready to go,
Possibly if not probably already approved and ready to go.

It could well have got emergency use approval....

The problem is they have chopped and
changed their minds several times rarely if ever taking anything to completion.

Therefore what could have been ready to go and made the company a fortune,
Was never completed because they just changed their mind
and thought the SARS Outbreak was over?

That's pretty slack and possibly shows that they like to use the latest thing to get attention,
As soon as it wasn't a big deal anymore they just abandoned it.

In 2001 it was a cancer test that never came to be anything,
Then there was a valuation of 67cents in October 2001 which has never occured,

*In November 2001 it was BIT 009 for HIV Treatment, (nearing 23 Years Ago)
*In May 2002 it was a Prostate Cancer Test CT-2 Cancer Test
*In November 2002 in was the CT-2 Test for colorectal cancer
*By 14 March 2003 They had a shareholder update on the Cancer Tests and BIT 009
Stating that "Biotron is in active discussions with potential partners for this technology"
* 1 July 2003 it was "POTENTIAL NEW THERAPY FOR HEPATITIS C" with a provisional patent being made
*27 July 2003 it was: "POTENTIAL NEW THERAPY FOR SARS" with a provisional patent application also being made
*3 September 2003 it was "RE: POTENTIAL NEW THERAPY FOR DENGUE" with another preliminary patent filed
*8 September 2005 BIT 225 was selected as their lead compound
*30 November 2005 "BIOTRON’S HIV DRUG IMPROVES ACTIVITY OF EXISTING HIV THERAPIES"
*24 Feb 2006 "BIOTRON COMPOUNDS ACTIVE AGAINST BIRD FLU"
"active against the H5N1 strain of influenza A virus, commonly known as the 'bird flu'."
*10 July 2007 "Biotron compounds have shown potent activity against the Hepatitis B virus (HBV)."
*7 August 2008 "PHASE Ib/IIa HCV CLINICAL TRIAL COMMENCED"
*6 October 2009 "SUCCESSFUL HCV TRIAL RESULTS"
*10 November 2009 "BIOTRON'S ANTI-HCV DRUG RECOGNISED INTERNATIONALLY"
*18 March 2010 "BIOTRON HCV DRUG: INTERNATIONAL PARTNER TO PROGRESS TRIAL "
*19 March 2010 "SHAREHOLDER UPDATE and PIGGY BACK OPTIONS OPPORTUNITY"
*29 September 2011 "LANDMARK HIV TRIAL UNDERWAY" phase 1B/2A
*10 October 2011 "HEPATITIS C PHASE 2A TRIAL POSITIVE RESULTS"
*7 December 2011 "BIOTRON ANNOUNCES POSITIVE THREE MONTH DATA FOR BIT225 - 87% VIRUS FREE" for HCV
*16 October 2012 "Biotron Limited to report new clinical data from BIT225 Hepatitis C Phase 2a trial in a late-breaking presentation at the AASLD 2012 annual conference - 100% of HCV trial patients receiving 400mg of BIT225 daily for 1 month, had undetectable virus at the 48 week time point"
*9 November 2012 "KEY PHASE 2 HIV/HCV TRIAL COMMENCED"
*14 December 2012 "BIOTRON COMPLETES CLINICAL STAGE OF HIV CLINICAL TRIAL"
*14 August 2013 "BIT225 CAPSULE FORMULATION TRIAL COMPLETED"
*25 October 2013 "BIT 225 ENHANCES ANTI- VIRAL ACTIVITY IN HIV/HCV GENOTYPE 3 COINFECTED PATIENTS; PHASE 2 DATA TO BE PRESENTED AT LEADING INTERNATIONAL LIVER MEETING"
*23 January 2014 "The Company is fully funded and on budget to complete its currently stated objectives, The Company also remains in dialogue with interested parties regarding commercialisation of the Company's antiviral compounds."
*13 February 2014 "KEY USA PATENT ALLOWED FOR BIOTRON'S BIT225"
*6 March 2014 "BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS"
*10 October 2014 "BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C"
*30 September 2015 "INTERIM DATA FROM BIT225-008 STUDY IN SUBJECTS WITH HEPATITIS C VIRUS GENOTYPE 3"
*3 December 2015 "POTENTIAL ERADICATION OF HIV RESEVOIRS DATA PUBLISHED"
*16 February 2016 "BIOTRON ANTI-VIRAL COMPOUNDS TO BE TESTED IN USA FOR ACTIVITY AGAINST ZIKA VIRUS"
*17 March 2016 "BIOTRON PHASE 2 HEPATITIS C TRIAL SUCCESS"
*23 May 2016 "BIOTRON COMPOUNDS DEMONSTRATE ACTIVITY AGAINST ZIKA VIRUS"
*15 June 2017 "UPDATE ON PROGRESS OF BIT225 PHASE 2 HIV-1 CLINICAL TRIAL"
 Trial headline results anticipated Q3 this year.
*15 November 2017 "BIOTRON COMPOUNDS DEMONSTRATE ACTIVITY AGAINST HEPATITIS B VIRUS"
*28 September 2018 "Significant Immunological Outcomes in BIT225 HIV-1 Clinical Trial"
*6 February 2020 "BIOTRON TO TEST ITS COMPOUNDS AGAINST CORONAVIRUS"
*7 September 2020 "BIOTRON COMPOUNDS SHOW ACTIVITY AGAINST SARS-CoV-2 VIRUS IN PRELIMINARY ASSAYS"
*1 November 2021 "COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS"
*25 November 2021 "BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS"
*14 September 2022 "BIT225 COVID-19 HUMAN STUDY COMMENCED"
*9 March 2023 "COMPLETION OF PHASE 2 HIV-1 CLINICAL TRIALS"
"We look forward to completing the detailed laboratory studies on the samples collected during the trials and reporting preliminary results in mid-2023.”
*4 May 2023 "COMMENCEMENT OF PHASE 2 COVID-19 CLINICAL TRIAL"
*16 August 2023 "COMPLETION OF PHASE 2 COVID CLINICAL TRIAL"
"Preliminary results are expected to be available in September 2023. "

You may notice that many things that were mentioned were never delivered,
But also how they have chopped
and changed what they are doing so many times,
Rarely completing one thing before moving onto another....